Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies.